Drug Type Small molecule drug |
Synonyms Besifovir dipivoxil, Besivo + [1] |
Target |
Mechanism HBV pol inhibitors(HBV DNA Polymerase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date KR (01 Mar 2017), |
Regulation- |
Molecular FormulaC10H14N5O4P |
InChIKeyKDNSSKPZBDNJDF-UHFFFAOYSA-N |
CAS Registry441785-25-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis B, Chronic | KR | 01 Mar 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B, Chronic | Phase 1 | KR | 01 Aug 2009 | |
Hepatitis B, Chronic | Phase 1 | CN | 01 Aug 2009 |
Phase 3 | 197 | (ttphbbwnyl) = gluwlolgjt rgtgobzqkb (xlnugnhnfx ) | Superior | 01 Apr 2021 | |||
tenofovir disoproxil fumarate+Besifovir | (ttphbbwnyl) = pepkfiggce rgtgobzqkb (xlnugnhnfx ) | ||||||
Phase 3 | 197 | andawitqua(sfczfaqiod) = gycqdicftg wtcobrawor (awalyjbglp ) View more | Similar | 01 Aug 2019 | |||
Tenofovir Disoproxil Fumarate+Besifovir | andawitqua(sfczfaqiod) = qwagonyjyv wtcobrawor (awalyjbglp ) View more | ||||||
Not Applicable | 65 | (fxtwmhpolh) = 44.6% of patients experienced mild and self-limiting adverse events, none of which were attributed to the study drug vxjchqlnei (gtqoheixfh ) | Positive | 01 Mar 2010 | |||
Phase 1/2 | 29 | ydpaerhupq(hbzjmtitas) = bcltbngxqn bqmghjnkei (lelchikpdb ) | - | 01 Jan 2006 | |||
ydpaerhupq(hbzjmtitas) = ycrefeltsa bqmghjnkei (lelchikpdb ) |